Results

Total Results: 1,571 records

Showing results for "discussed".

101. Disposition of Comments for CER 162 Diagnosis of Celiac Disease (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/celiac-disease_disposition-comments.pdf
     January 28, 2016 - These studies were relatively rare; but we did include some and their strengths and weakness are discussed … Commentator & Affiliation Section Comment Response report so that VCE is always discussed after … One issue that can be additionally discussed is the different HLA DQ2 haplotypes and methods for HLA … This issue is now discussed in the Executive Summary and Discussion section under “Applicability.”

102. Disposition of Comments for CER 175 Total Worker Health (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/worker-health_disposition-comments.pdf
     May 31, 2016 - Key Question 1 does not include the need to assess what is meant by integration nor the issues discussed … The timing of the studies should have been discussed in relation to the development of the TWH definition … The authors should add a discussion of limitations discussed in the response to question 1 of this … TWH may well have value, but for the reasons stated above and many more discussed by the authors, there … Key Question 1 does not include the need to assess what is meant by integration nor the issues discussed

103. Evidence-based Practice Center Systematic Review Protocol (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/hepatitis-c_research-protocol.pdf
     November 30, 2011 - The issue of adherence to antiviral treatment and outcomes was considered and discussed by AHRQ. … effectiveness of different treatment regimens among various patient subgroups defined by the characteristics discussed … Key Informants discussed the importance of a thorough understanding of the comparative effectiveness

104. Disposition of Comments for CER 161 Major Depressive Disorder (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/major-depressive-disorder-disposition-160504.pdf
     December 08, 2015 - Another issue that needs to be more explicitly discussed is that there may well be sample bias depending … I believe that the approaches being discussed in this review are better described as complementary … Indeed each of the treatment approaches, such as acupuncture is discussed in conjunction with SGA, … The same would be true elsewhere in the document and abstract where acupuncture is discussed. … This is problematic for the reasons discussed above. Thank you for the comment.

105. Disposition of Comments Report for Technical Brief 15 Transition Care for Children With Special Health Needs (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/children-special-needs-transition_disposition-comments.pdf
     June 17, 2014 - We did not limit the types of evidence that could be reviewed and discussed for Guiding Questions … We did not limit the types of evidence that could be reviewed and discussed for Guiding Questions … We did not limit the types of evidence that could be reviewed and discussed for Guiding Questions … As it discussed in many HCT articles, it is critical that the term "transition” and “transfer” are … Peer Reviewer 13 General The limitations of measures (materials) was not discussed.

106. Disposition of Comments Report for Interventions To Modify Health Care Provider Adherence to Asthma Guidelines (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/asthma-provider-adherence_disposition-comments.pdf
     May 19, 2013 - Key Question 3 I believe that improved control is a patient outcome of significance that is not discussed … Magnitude is listed on the data tables but is not always discussed.

107. Disposition of Comments for CER 196 The Role of Immunotherapy in the Treatment of Asthma (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/cer-196-disposition-comments-immunotherapy-asthma.pdf
     March 23, 2018 - The reason for performing this review is nicely discussed. Thank you for your comment. … in this paragraph, but prior to this paragraph no other studies have been cited in this way when discussed … It is further recommended that this omission should also be discussed carefully in the Discussion Section … in the discussion, otherwise it is not clear if it is antigen specific or total IgE that is being discussed … Individual reactions will be discussed in their respective RCT and non- RCT categories." therefore we

108. Disposition of Comments for CER 182 Glasgow Coma Scale (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/field-triage-glascow-disposition-170415.pdf
     January 12, 2017 - , described in the Methods section, two reviewers independently rated the quality of each study, discussed … This is discussed in the article cited by the reviewer: “simpler scales perform just as well.” tGCS … As described in the Methods section, two reviewers independently rated the quality of all studies, discussed … Response Peer Reviewer #5 Results I guess the one thing that is not clear in the way the results are discussed … I realize this is discussed on page 55 but I think you can be less perfunctory here or repeat it in

109. Making Healthcare Safer IV Rapid Review: Prevention in Adults of Infection With Transmission of Multidrug-Resistant Organisms (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/mhs4-infection-prevention-mdro-rapid-research.pdf
     April 01, 2024 - associated pneumonia/events (VAP/VAE), surgical site infection (SSI), surveillance testing (will be discussed … separate MHS IV chapter), as well as the broader practices of antimicrobial stewardship (which was discussed … Conflicts were discussed and resolved during a team meeting. … The authors discussed in detail a number of methodologic and analytic problems with studies, including … There was also literature which discussed the use of several of these practices in combination in long-term

110. Ch 2-User-Guide-To-Ocer 130129 (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/ch_2-user-guide-to-ocer_130129.pdf
     January 01, 2011 - the appropriate data source, patient population, inclusion/exclusion criteria, and comparators are discussed … As discussed, the cohort design provided a clear timeline, differentiating exposure from potential … should be the default design for CER studies; deviations should be argued for and their consequences discussed … Some additional study designs have not been discussed. … Many of the issues that will be discussed in the following chapters about ways to deal with treatment

111. Interventions Targeting Sensory Challenges in Children With Autism Spectrum Disorders - An Update (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/asd-interventions-disposition.pdf
     May 26, 2017 - and I believe this is not adequately accounted for in the assessment of the studies, or adequately discussed … Cochrane)and discussed why the results of those reviews might differ from the AHRQ.

112. Disposition of Comments for Technical Brief 22 Environmental Cleaning for the Prevention of Healthcare-Associated Infections (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/healthcare-infections_disposition-comments.pdf
     August 10, 2015 - However, we focused the report on the three pathogens of interest as discussed above. … Part of this is discussed in the section on patient safety culture (page 16 and following), but a key … While the ‘cidal’ activity of each of the surface disinfectants is discussed, this isn’t addressed … Our systematic searches did not identify any studies that specifically examined or discussed the percent … It really is that they have “not been established”, as previously discussed.

113. Effectiveness of Screening and Treatment of Subclinical Hypothyroidism or Hyperthyroidism (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/hypothyroidism-hyperthyroidism-screening-treatment_disposition-comments.pdf
     February 01, 2012 - , 2nd We have added language briefly describing the Whickham study in the paragraph in which it's discussed … agree that this might be the case, but we would need future research to confirm and have briefly discussed … Again the last sentence (line 12-14) is problematic as this is not referenced or further discussed in

114. Disposition of Comments for CER 165 Fecal Incontinence (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/fecal-incontinence_disposition-comments.pdf
     March 21, 2016 - We discussed the non-neurologic and neurologic distinction with our experts prior to this review (KIs … quality of the literature evidence for SNS to date is weak due to methodological limitations that were discussed … One the most common outcome measure, the bowel diary, is not well-discussed as a tool to measure FI

115. Maternal, Fetal, and Child Outcomes of Mental Health Treatments in Women: A Systematic Review of Perinatal Pharmacological Interventions (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/cer-236-maternal-fetal-child-outcomes-disposition-comments.pdf
     April 15, 2021 - For all of the other major complications that are discussed in the review, it would be useful to include … It would also be helpful to include information on neonatal adaptation syndrome, which is not discussed … than as part of the information on respiratory difficulties where some of this information is already discussed … Particularly if the studies are often discussed or cited by other reviews or meta-analyses, it is important

116. Disposition of Comments for Screening of Methicillin-Resistant Staphylococcus Aureus (MRSA) (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/mrsa-screening-2010_disposition-comments.pdf
     January 01, 2010 - The epidemiology is briefly discussed as are conventional strategies for MRSA control. … While the findings are not conclusive, this topic should be discussed in more depth. … This subject is discussed in the Introduction. … We have discussed these issues in the report. … We have discussed this concern as a potential harm of screening for MRSA carriage.

117. Politi (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/politi.pdf
     May 29, 2025 - Politi Slide  1: Supporting  Shared Decisions When Clinical Evidence  is Low Mary C. Politi, Ph.D. Department of Surgery, Division of  Public Health Sciences Washington University in St. Louis School of Medicine Slide  2: Overview • Brief overview of Shared Decis…

118. Disposition of Comments Report for The Effectiveness and Risks of Long-Term Opioid Treatment of Chronic Pain (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/chronic-pain-opioid-treatment_disposition-comments.pdf
     September 29, 2014 - Comparisons with prior reviews are concisely and clearly discussed. … The mentioned reviews and others are Discussed for contextual purposes. … I would also recommend consistency in the report in the order in which these are discussed. … This association is not intuitive and is not commonly discussed. … The results of the American Pain Society review are discussed throughout the report.

119. Disposition of comments_Comparative Effectiveness Review No. 242: Radiation Therapy for Brain Metastases (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/cer-242-radiation-therapy-brain-metastases-disposition-comments.pdf
     June 09, 2021 - In addition, the key questions listed demonstrate the main points discussed in the entire report. … Reviewer #1 Results Page 56-57 of 280 Serious adverse events- Please include citations for the studies discussed … 57 of 280 No. of adverse events and Radiation necrosis- Please include citations for the studies discussed … Peer Reviewer #1 Results Page 57-58 of 280 Headaches- Please include citations for the studies discussed … #1 Results Page 59 of 280 Fatigue, Seizure, Vomiting- Please include citations for the studies discussed

120. Disposition of Comments CER 214 Stroke Prevention in Patients With Atrial Fibrillation (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/cer-214-afib-disposition-comments.pdf
     October 30, 2019 - don’t think you necessarily need to change the inclusion criteria at this point, but this should be discussed … As discussed there is sparse data evaluating direct comparisons. 118. … The study by Hijazi was included in our report and is discussed in the subgroup table within KQ3. … rivaroxaban for nonvalvular AF;” however BI notes that data from Gorst-Rasmussen et al. (2016) is not discussed … Peer Reviewer #5 Clarity/ Usability See general comments (#s 24-36) No response needed – discussed